EMD-41617

Single-particle
3.12 Å
EMD-41617 Deposition: 15/08/2023
Map released: 15/11/2023
Last modified: 28/05/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-41617

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-8tu6 summary report (pdf.gz) Map-8tu6 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

CryoEM structure of PI3Kalpha

EMD-41617

Single-particle
3.12 Å
EMD-41617 Deposition: 15/08/2023
Map released: 15/11/2023
Last modified: 28/05/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: PI3Kalpha
Fitted models: 8tu6

Deposition Authors: Valverde R , Shi H, Holliday M , Sun M
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3K alpha Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
PUBMED: 37916956
DOI: doi:10.1158/2159-8290.CD-23-0944
ISSN: 2159-8290
Grant Support: